Drugs / RO5028442
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01474278 | Dec 2011 → Mar 2013 | autism | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO5028442 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01474278 ↗ |
| Action | Inhibit | “blockade of the V1a receptor” PMID 27711048 ↗ Oct 2016 |
| Modality | Small molecule | — CHEMBL3416885 ↗ |
| Route | Intravenous | “a single 20 mg intravenous dose” PMID 27711048 ↗ Oct 2016 |
| Target | AVPR1A | “the arginine vasopressin receptor 1A (V1a) antagonist” PMID 27711048 ↗ Oct 2016 |